GEO Publications
Handout
NAR 2024 (latest)
NAR 2002 (original)
All publications
FAQ
MIAME
Email GEO
NCBI
>
GEO
>
Accession Display
Not logged in |
Login
GEO help:
Mouse over screen elements for information.
Scope:
Self
Platform
Samples
Series
Family
Format:
HTML
SOFT
MINiML
Amount:
Brief
Quick
GEO accession:
Sample GSM39512
Query DataSets for GSM39512
Status
Public on Apr 01, 2005
Title
ms143-2
Sample type
RNA
Source name
Staged C. elegans embryos
Organism
Caenorhabditis elegans
Extracted molecule
total RNA
Description
Mutant genotype mex-3(zu155); skn-1(RNAi) 143 minutes after the 4-cell embryonic stage at 22 degrees C
Sample_genotype: ms
Sample_time: 143
Submission date
Jan 24, 2005
Last update date
May 27, 2005
Contact name
Andrew Hill
E-mail(s)
andrew.hill@pfizer.com
Phone
617-674-6341
Organization name
Pfizer
Department
Research Business Technology
Street address
300 Technology Square
City
Cambridge
State/province
MA
ZIP/Postal code
02139
Country
USA
Platform ID
GPL200
Series (1)
GSE2180
C. elegans embryonic timecourse in wt and mutant embryos
Data table header descriptions
ID_REF
Affymetrix Qualifier
VALUE
RMA calulated using Bioconductor Affy package (http://www.bioconductor.org)
Data table
ID_REF
VALUE
171720_x_at
4.26772508325331
171721_x_at
5.82210314378443
171722_x_at
7.00855136894527
171723_x_at
3.33185139115781
171724_x_at
4.73305588507035
171725_x_at
3.9557498273122
171726_x_at
4.42317144532363
171727_x_at
3.01082562378534
171728_x_at
2.67708357754770
171729_x_at
7.34011113347295
171730_x_at
2.49263035800154
171731_x_at
8.07137438513936
171732_x_at
6.52250331526868
171733_x_at
8.44751732316289
171734_x_at
9.19123007403184
171735_x_at
3.18506053517752
171736_x_at
7.9661223843549
171737_x_at
8.19422661556945
171738_x_at
4.97622489624737
171739_x_at
3.19865352197933
Total number of rows:
22625
Table truncated, full table size
608 Kbytes
.
Supplementary file
Size
Download
File type/resource
GSM39512.CEL.gz
2.7 Mb
(ftp)
(http)
CEL
GSM39512.EXP.gz
331 b
(ftp)
(http)
EXP
|
NLM
|
NIH
|
GEO Help
|
Disclaimer
|
Accessibility
|
